Bubendorf/Basel, 7 February 2017 – The Bachem Group (SIX: BANB) announced today the renewal of its supply agreement with AstraZeneca for the peptide active substance Goserelin. The extended partnership enhances the successful cooperation between both companies. Under the terms of the agreement, AstraZeneca will continue acquiring the peptide active substance Goserelin from Bachem for the next five years. Bachem has been supplying AstraZeneca with Goserelin for more than 25 years.